AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02539992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® CR/Neutral Overall Limb Alignment
Description: Total knee replacement using patient-specific cutting guides
Study NCT02539992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon® CR/Conventional Limb Alignment
Description: Total knee replacement using traditional instrumentation
Study NCT04126304 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
Study NCT04126304 — intervention group
Intervention type: DRUG
Intervention: non-macrolides antibiotics
Description: If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
Study NCT04126304 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mycoplasma detection
Description: 1. common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~2. community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection
Study NCT04126304 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: 1. Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~2. Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~3. Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.
Study NCT04126304 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
Study NCT02757729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.1%
Description: Topical application
Study NCT02757729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application
Study NCT02757729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application
Study NCT02757729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study NCT00346957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 30 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months
Study NCT00346957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 15 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months
Study NCT00346957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 3 mg
Description: 0.5ml administered onto the sclera once every six months for 24 months
Study NCT00346957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: 0.5ml administered onto the sclera once every six months for 24 months
Study NCT01309386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Description: Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
Study NCT01309386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine SR
Description: Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
Study NCT03139734 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sacral Neuromodulation
Description: S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
Study NCT01949389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy for Insomnia
Description: This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
Study NCT00596700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Given® Diagnostic System including PillCamTM SB Capsules
Description: Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa
Study NCT00830505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol
Description: 2 puffs twice a day for 2 weeks
Study NCT00830505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: 2 puffs twice a day for 2 weeks
Study NCT02918305 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PRDS-001 Renal Denervation Ultrasound System
Study NCT02918305 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Study NCT03765008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water intake manipulation
Description: for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
Study NCT03765008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water intake manipulation
Description: for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (Peg-IFN)
Description: Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing >75 kg.
Study NCT01240096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg daily
Study NCT01240096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 15 mg daily
Study NCT04596969 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch
Study NCT04596969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Fiber Dextrin
Description: Ingredient based on resistant starch
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing >75 kg.
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PBO)
Description: Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
Study NCT00704405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBO)
Description: Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
Study NCT04225689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD-TREAT diet
Description: Dietary intervention
Study NCT05564260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kaleidescope
Description: watching kaleidescope
Study NCT05564260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: wearing virtual reality glasses
Study NCT01500811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell injection
Description: Intra articular injection of chondrocyte
Study NCT03638167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR806-specific chimeric antigen receptor (CAR) T cell
Description: Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
Study NCT04520503 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
Study NCT04520503 — intervention group
Intervention type: DEVICE
Intervention: EEG monitoring
Description: The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
Study NCT03499145 — intervention group
Intervention type: DEVICE
Intervention: Ophthalmology diagnostic system.
Description: An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
Study NCT01044225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
Study NCT01044225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilengitide EMD 121974
Description: A dose of 2000 mg by IV administration 2 weekly.
Study NCT01844960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Gastric Band Insertion
Description: Insertion of gastric band though single abdominal incision
Study NCT01844960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Incision Gastric Band Insertion
Description: Insertion of gastric band though multiple abdominal incisions
Study NCT04625179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin and hyaluronic acid and sinus membrane elevation
Description: 3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
Study NCT04625179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus membrane elevation without any materials
Description: No materials will be placed at the sinus space.
Study NCT00890448 — intervention group
Intervention type: OTHER
Intervention: Pharmacogenomic whole blood sampling
Description: 10 mL, whole blood, one sample on Visit 2
Study NCT03020485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
Study NCT03020485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose is normal table sugar
Study NCT00475137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
Study NCT00475137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
Study NCT03007303 — intervention group
Intervention type: DRUG
Intervention: Atypical Antipsychotic
Description: Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
Study NCT03007303 — intervention group
Intervention type: OTHER
Intervention: atypical antipsychotic combined with MECT
Description: The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
Study NCT02479555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate injection, USP, 4 mg/mL
Description: Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device.
Study NCT00455169 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Influenza vaccine
Study NCT01611623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Tablets dose every other day; dose escalation based on safety
Study NCT04530045 — intervention group
Intervention type: OTHER
Intervention: dosage of concentration of piperacillin and cefepim
Description: Dosage of total plasma concentration of piperacillin and cefepim at different timepoints
Study NCT03065491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combined nutraceutical
Description: Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
Study NCT03065491 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 1 tablet per day
Study NCT03472638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
Study NCT03534661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide + Normal Saline
Description: Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
Study NCT03534661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide + L-NMMA
Description: Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
Study NCT03534661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + L-NMMA
Description: Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
Study NCT02147613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
Study NCT02147613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: 3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
Study NCT01129401 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stonewall Project
Description: The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
Study NCT01951144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo
Description: PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
Study NCT01951144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865 or Placebo or Lorazepam
Description: Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
Study NCT02976519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 443651
Description: twice daily
Study NCT02976519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT03069872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
Study NCT03006536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Li-ESWT
Description: Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
Study NCT03006536 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Li-ESWT
Description: Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
Study NCT04288947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Disrespect and Abuse in Maternity Care
Description: Changing the culture of disrespect and abuse in maternity care
Study NCT05380245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg x 2 Tablets
Description: Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
Study NCT05380245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg x 1Tablets
Description: Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
Study NCT00584584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study NCT00584584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04630678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: Virtual reality games were applied to participants for 30 minutes.
Study NCT04630678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
Study NCT04630678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.
Study NCT04630678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Training
Description: Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
Study NCT03263455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping group
Description: The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching.